Clinical Study Of Migraine Evolution

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00460005
First received: April 12, 2007
Last updated: April 14, 2008
Last verified: April 2008
  Purpose

Understanding the speed at which migraine headaches develop is of importance to patients. Determining the proportions in which different headache pain build-up occurs, may provide health care practitioners with valuable information with which to prescribe the most appropriate treatment. Patients who experience a slow pain build-up may gain more benefit from medications which have a slow onset of effect, high tolerability and long action. Conversely, medications with a rapid onset of effect may be of greater benefit to patients who experience rapid onset of migraine pain.


Condition Phase
Migraine Headache
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: A Multicenter Study to Determine the Clinical Characteristics of the Temporal Aspects of Migraine in a Canadian Population: Clinical Study Of Migraine Evolution (C-SOME)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Estimated Enrollment: 250
Study Start Date: January 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is outpatient.
  • Subject has a diagnosis of migraine with/without aura according to IHS criteria, of at least 1 years duration.
  • Subject is able to comprehend the study procedures and to comply with study requirements.

Exclusion Criteria:

  • Subject has other chronic pain condition(s) not associated with migraine
  • Subject is unable to understand the schedule/questionnaire.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00460005

Locations
Canada, Alberta
GSK Clinical Trials Call Centre
Calgary, Alberta, Canada, T2N 2T9
Canada, British Columbia
GSK Clinical Trials Call Centre
Richmond, British Columbia, Canada, V6X 1A3
GSK Clinical Trials Call Centre
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, New Brunswick
GSK Clinical Trials Call Centre
Saint John, New Brunswick, Canada, E2L 4L2
Canada, Nova Scotia
GSK Clinical Trials Call Centre
Halifax, Nova Scotia, Canada, B3H 3A7
Canada, Ontario
GSK Clinical Trials Call Centre
Hamilton, Ontario, Canada, L8N 1Y2
GSK Clinical Trials Call Centre
Toronto, Ontario, Canada, M5S 1B6
GSK Clinical Trials Call Centre
Unionville, Ontario, Canada, L3R 0W7
Canada, Quebec
GSK Clinical Trials Call Centre
Longueuil, Quebec, Canada, J4L 4N5
GSK Clinical Trials Call Centre
Montreal, Quebec, Canada, H3A 2B4
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, M.D. GlaxoSmithKline
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00460005     History of Changes
Other Study ID Numbers: S2W106188
Study First Received: April 12, 2007
Last Updated: April 14, 2008
Health Authority: Canada: Health Canada

Keywords provided by GlaxoSmithKline:
Migraine
headache
observational

Additional relevant MeSH terms:
Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on September 22, 2014